Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy-Reference-Cited by-同舟云学术

Study APV20002: Safety and Efficacy Results Through Week 684 for Pediatric Participants Living with HIV-1 Treated with Ritonavir-Boosted Fosamprenavir Oral Solution–Based Antiretroviral Therapy

Published:2024-07-19 Issue: Volume: Page:
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Ross Lisa L.¹,Cotton Mark F.²,Cassim Haseena³,Garges Harmony P.¹,van Dijkman Sven C.⁴,Morarji Kishen⁴,Karthika Supriya⁴,Danehower Susan¹,Radford Jacob⁴,Butcher David⁵

Affiliation:

1. ViiV Healthcare, Durham, North Carolina, USA.

2. Department of Pediatrics and Child Health, Children’s Infectious Diseases Clinical Research Unit, Stellenbosch University, Tygerberg, South Africa.

3. Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

4. GlaxoSmithKline, Brentford, United Kingdom.

5. ViiV Healthcare, Brentford, United Kingdom.

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2024.0020

Reference7 articles.

1. Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data

2. Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens

3. Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children

4. “A problem shared is half solved” – a qualitative assessment of barriers and facilitators to adolescent retention in HIV care in western Kenya

5. Retention and adherence